Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Substance in tears could be used for diabetes monitoring

Publish date:: October 16, 2020

Key clinical point: Glycated albumin (glycoalbumin) in tears could someday be a way for those with diabetes to monitor their blood sugar levels noninvasively.

Major finding: Tears and blood were strongly correlated (r = .722; P < .001) even after adjustment for age, gender, nephropathy stage, and obesity.

Study details: A study of 100 patients with diabetes. Tear and blood samples were collected and GA levels measured.

Disclosures: The study was funded by a grant from the Japan Agency for Medical Research and Development. The study’s investigators had no conflicts of interest.

Citation:

Aihara M. EASD 2020, poster presentation 624.

This Week's Must Reads

Higher dose maximizes effects of magnesium sulfate for obese women,

Microplastics permeate human placentas,

One in five gestational carriers do not meet ASRM criteria,

Gender surgical outcomes differ following puberty suppression,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Diabetes

Sac/val heart failure benefit extends to diabetes patients,

Don’t miss cardiovascular risk factors in transgender patients,

Semaglutide shows promise in NASH phase 2 study,

‘Modest’ benefit for post-MI T2D glucose monitoring,

Diabetic neuropathic pain linked to brain bioenergic anomalies,